ЯEGENERA GmbH Modecenterstrasse, 22/D01 1030 Vienna – Austria regenera.at info@regenera.at VAT ATU78924559 FN587445s

Vienna, 17.04.2024

PRESS RELEASE

We are pleased to announce that, following the positive opinion of the European Medicines Agency's Committee for Orphan Medicinal Products, on the 16th of April, 2024, the European Commission granted the ***orphan medicinal product designation*** to our SpinoSave® product for the treatment of subacute spinal cord injury.

Our treatment is granted the orphan designation under nr. EU/3/24/2909.

The European Medicines Agency's Committee for Advanced Therapies has previously (16.02.2023) classified SpinoSave® as an **Advanced Therapy Medicinal Product** (ATMP) under the subclassification of **Tissue Engineered Product** (TEP).

Our treatment classification has been issued under nr. EMA/CAT/12870/2023.

Our SpinoSave® therapy consists in the use of autologous adipose tissue derived mesenchymal progenitor cells captured in biodegradable chemically crosslinked hydrogel to treat subacute spinal cord injury in adults with lesion with ASIA A score.

Giuseppe Perale, CEO - Michael Raghunath, CMO